Karyopharm Therapeutics Inc (KPTI)

12:32 PM

Karyopharm to seek label expansion for Xpovio in myelofibrosis after late-stage trial win - MSN

12:32 PM

Apr 15, 2026

KPTI stock slumps pre-market even as Karyopharm’s myelofibrosis treatment meets primary endpoint — retail doubtful about FDA approval - MSN

Apr 15, 2026

Apr 15, 2026

Karyopharm Therapeutics (KPTI) price target decreased by 22.08% to 12.24 - MSN

Apr 15, 2026

Apr 14, 2026

Karyopharm Therapeutics jumps 18%, raises $30M privately - MSN

Apr 14, 2026

Apr 13, 2026

Karyopharm Therapeutics (KPTI) affiliated managers report 1.9%–2.3% stakes - Stock Titan

Apr 13, 2026

Apr 13, 2026

[ARS] Karyopharm Therapeutics Inc. SEC Filing - Stock Titan

Apr 13, 2026

Apr 13, 2026

Karyopharm (KPTI) seeks approval for director slate and larger equity plans - Stock Titan

Apr 13, 2026

Apr 13, 2026

Gains Report: Can Karyopharm Therapeutics Inc disrupt its industry2026 Investor Takeaways & Daily Profit Maximizing Tips - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

KPTI Receives Reiterated "Buy" Rating from HC Wainwright & Co. | KPTI Stock News - GuruFocus

Apr 12, 2026

Apr 10, 2026

Portfolio Update: Will Karyopharm Therapeutics Inc stock benefit from M A2026 Stock Rankings & Safe Entry Point Identification - baoquankhu1.vn

Apr 10, 2026

Apr 08, 2026

Quarterly Earnings: How sensitive is Karyopharm Therapeutics Inc to inflationPortfolio Gains Report & AI Enhanced Trading Alerts - baoquankhu1.vn

Apr 08, 2026

Apr 07, 2026

RBC Capital Adjusts Karyopharm Therapeutics PT to $16 From $23, Maintains Outperform Rating - Moomoo

Apr 07, 2026

Apr 06, 2026

Dip Buying: Is Karyopharm Therapeutics Inc attractive for institutional investors2026 Update & Growth Oriented Trading Recommendations - baoquankhu1.vn

Apr 06, 2026

Apr 03, 2026

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Apr 03, 2026

Apr 02, 2026

RA Capital (NASDAQ: KPTI) and partners report 9.99% stake in Karyopharm - Stock Titan

Apr 02, 2026

Apr 02, 2026

Commodore Group discloses 1.95M KPTI stake; 19,618,032 shares O/S - Stock Titan

Apr 02, 2026

Apr 02, 2026

Karyopharm Therapeutics Inc. R (25K0.DU) insider ownership and holdings - Yahoo Finance Australia

Apr 02, 2026

Mar 31, 2026

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Up 20.9% in March - MarketBeat

Mar 31, 2026

Mar 31, 2026

Will Karyopharm Therapeutics Inc benefit from green energy policiesInsider Buying & Safe Capital Growth Trade Ideas - baoquankhu1.vn

Mar 31, 2026

Mar 30, 2026

Piper Sandler Lowers Price Target for Karyopharm Therapeutics (K - gurufocus.com

Mar 30, 2026

Mar 30, 2026

Piper Sandler Reaffirms "Overweight" Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat

Mar 30, 2026

Mar 30, 2026

Karyopharm stock price target cut to $8 by Piper Sandler on trial results - ca.investing.com

Mar 30, 2026

Mar 27, 2026

Karyopharm Therapeutics Inc (KPTI) Stock Price, Quote, News & History - benzinga.com

Mar 27, 2026

Mar 27, 2026

Karyopharm Strengthens Liquidity With New Equity Financing - tipranks.com

Mar 27, 2026

Mar 27, 2026

Karyopharm Therapeutics raises $30 million in private placement with RA Capital - Investing.com Australia

Mar 27, 2026

Mar 27, 2026

Karyopharm Therapeutics raises $30 million in private placement with RA Capital By Investing.com - Investing.com South Africa

Mar 27, 2026

Mar 27, 2026

Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar? - Yahoo Finance

Mar 27, 2026

Mar 27, 2026

HC Wainwright Has Optimistic Outlook of KPTI Q1 Earnings - MarketBeat

Mar 27, 2026

Mar 27, 2026

Karyopharm Therapeutics raises ~$30M in private placement, adds ~$19.8M via ATM - TradingView

Mar 27, 2026

Mar 27, 2026

Karyopharm (NASDAQ: KPTI) completes $30M private placement and ATM sale - Stock Titan

Mar 27, 2026

Mar 26, 2026

Karyopharm: Putting The Phase 3 Trial In Context (NASDAQ:KPTI) - Seeking Alpha

Mar 26, 2026

Mar 25, 2026

KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data - Yahoo Finance

Mar 25, 2026

Mar 25, 2026

KPTI: Baird Lowers Price Target, Maintains Outperform Rating | K - GuruFocus

Mar 25, 2026

Mar 25, 2026

Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $15.00 at Robert W. Baird - MarketBeat

Mar 25, 2026

Mar 25, 2026

HC Wainwright Lowers Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $8.00 - MarketBeat

Mar 25, 2026

Mar 25, 2026

H.C. Wainwright cuts Karyopharm stock price target on trial results By Investing.com - Investing.com Canada

Mar 25, 2026

Mar 25, 2026

HC Wainwright & Co. Lowers Price Target on Karyopharm Therapeuti - GuruFocus

Mar 25, 2026

Mar 25, 2026

Karyopharm raises $30M in private placement with RA Capital By Investing.com - Investing.com Australia

Mar 25, 2026

Mar 25, 2026

Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark - Sahm

Mar 25, 2026

Mar 25, 2026

Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in MyelofibrosisSlideshow (NASDAQ:KPTI) 2026-03-25 - Seeking Alpha

Mar 25, 2026

Mar 25, 2026

Karyopharm myeloma drug yields mixed data in myelofibrosis trial - BioPharma Dive

Mar 25, 2026

Mar 24, 2026

Karyopharm’s myelofibrosis trial meets one of two primary goals By Investing.com - Investing.com India

Mar 24, 2026

Mar 24, 2026

KPTI Shares Fall Following Varied Results from Phase III Myelofibrosis Combination Study - Bitget

Mar 24, 2026

Mar 24, 2026

Karyopharm Therapeutics falls as pivotal trial hits spleen goal but misses symptom mark - msn.com

Mar 24, 2026